
|Articles|October 18, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
The Utility of Pomalidomide in R/R Multiple Myeloma
Author(s)Manish Sharma, MD
Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.
Advertisement
Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.
In an updated analysis of the phase III MM-003 trial, Celgene International Sarl reported on a new progression-free survival analysis and final overall survival.
Articles in this issue
over 12 years ago
Clinical Advances in Mantle Cell Lymphomaover 12 years ago
Emerging Therapies for the Treatment of Mantle Cell Lymphomaover 12 years ago
In Brief: Phase III Trials in Multiple Myelomaover 12 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?over 12 years ago
Transforming Expectations and Outcomes With Targeted TherapiesAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5

















